The North East and North Cumbria (NENC) Medicines Committee are seeking NENC system-wide views on implementation of NICE TA888: Risankizumab for previously treated moderately to severely active Crohn’s disease, as outlined in the consultation document.
Comments are welcomed from across the system, including residents and patients of the NENC. Comments will be returned to the medicines committee, or its sub-committee, and used to inform implementation of the decisions in NENC.
This consultation will run for four weeks and closes at 5pm on Wednesday 14th June 2023. Take part by visiting the consultations page.